Amgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Source: aol.com
Page 13 - David Ricks News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from David Ricks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In David Ricks Today - Breaking & Trending Today
Patients on hunt for diabetes, obesity and weight-loss drugs – Indianapolis Business Journal
Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.
Source: ibj.com
Eli Lilly soars 8% after Q1 earnings reveal surging popularity for its Zepbound weight-loss drug
"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's conference call.
Source: yahoo.com
Eli Lilly Stock Rises: Q1 Earnings Show Demand for Zepbound Weight-Loss Drug
"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's conference call.
Source: businessinsider.com